Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Capricor Therapeutics (CAPR)
NASDAQ:CAPR
reports
Capricor Therapeutics (CAPR) Stock Price & Analysis
574 Followers
CAPR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.81 - $6.58
Previous Close$4.2
Volume89.79K
Average Volume (3M)122.28K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$46.61M
Total Debt (Recent Filing)$2.78M
Price to Earnings (P/E)-3.7
Beta-0.22
Next EarningsMar 15, 2023
EPS Estimate-$0.34
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$15.00
EPS (TTM)-1.13
Shares Outstanding25,241,402
R-Squared0.11
Standard Deviation0.68
10 Day Avg. Volume163,398
30 Day Avg. Volume122,285
Price to Book (P/B)6.90
Price to Sales (P/S)67.09
Price to Cash Flow (P/CF)16.60
P/FCF Ratio11.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside257.14% Upside
Rating ConsensusModerate Buy
Alpha0.03
Number of Analyst Covering2
Capricor Therapeutics News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CAPR FAQ
What was Capricor Therapeutics’s price range in the past 12 months?
Capricor Therapeutics lowest stock price was $2.81 and its highest was $6.58 in the past 12 months.
What is Capricor Therapeutics’s market cap?
Currently, no data Available
When is Capricor Therapeutics’s upcoming earnings report date?
Capricor Therapeutics’s upcoming earnings report date is Mar 15, 2023 which is in 40 days.
How were Capricor Therapeutics’s earnings last quarter?
Capricor Therapeutics released its earnings results on Nov 10, 2022. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.32 by $0.06.
Is Capricor Therapeutics overvalued?
According to Wall Street analysts Capricor Therapeutics’s price is currently Undervalued.
Does Capricor Therapeutics pay dividends?
Capricor Therapeutics does not currently pay dividends.
What is Capricor Therapeutics’s EPS estimate?
Capricor Therapeutics’s EPS estimate is -$0.34.
How many shares outstanding does Capricor Therapeutics have?
Capricor Therapeutics has 25,241,402 shares outstanding.
What happened to Capricor Therapeutics’s price movement after its last earnings report?
Capricor Therapeutics reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.32. Following the earnings report the stock price went down -7.143%.
Which hedge fund is a major shareholder of Capricor Therapeutics?
Among the largest hedge funds holding Capricor Therapeutics’s share is Oracle Investment Management Inc. It holds Capricor Therapeutics’s shares valued at N/A.
---
Capricor Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00
$15.00
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $26.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.29%
12-Months-Change
Fundamentals
Return on Equity
-105.40%
Trailing 12-Months
Asset Growth
25.12%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Capricor Therapeutics
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.
---
---